While most of the financial world focuses on creating and trading new exchange traded contracts, GREENEYE will focus on creating a much more profitable OTC 'world',combining market makers, retail bookmaking, centralized marketing and a high performance trading platform that enables brokers and their clients to transact business instantly with no paper work, and to monitor their positions, profit and loss, and risk in real time. The GREENEYE platform will provide leveraged, margined trading and an exciting VISUAL TRADING. and increasingly game-like user interface. The exchange-traded model has significant cost and control disadvantages for brokers and their clients.

This OTC bookmaking model has already been validated by VC, tier 1 Private Equity and Investment Bank investments in at least six separate transactions summing to nearly US$1B of investment into retail margined FX businesses this last few years. The investors have included Francisco Partners, General Atlantic Partners and Goldman Sachs. In late 2007 there was an acceleration of investment as the benefits and potential of the OTC opportunities became more apparent. Having said that none of these companies to our knowledge has a model which provides the mainstream retail brokers with the ability to keep their clients, access these markets and make better than broking returns.

Goldman Sachs' recent purchase of ten per cent of CMC valuing CMC at nearly US$4B, or twice the January 2008 value of Etrade, exemplifies the higher value of the OTC CFD business model not only in FX but also in equities where the exchanges have typically dominated trading volumes. (Etrade has over four million clients and US$180B in customer equity, yet strains to make a profit as an online broker in exchange traded products.)

GREENEYE offers mainstream agency brokers highly profitable new OTC business without departing from their agency business model and without passing their clients to third party margined brokers.